Eli Lilly Stock - Citi reiterates Buy rating with $1,500 target
17.06.2026 - 19:01:11 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:00 CET. Details in the imprint.
Eli Lilly & Co. (US5324571083) remains firmly on Wall Street's buy lists. Citi today maintained its Buy rating and a $1,500 price target, according to a report cited by The Globe and Mail.
All news and analysis on Eli Lilly stock
Current research views and company disclosures give investors a structured picture of how Eli Lilly is positioned in big pharma and obesity drugs.
Citi sticks with bullish view
The Citi note keeps Eli Lilly among its preferred healthcare picks. The analyst reiterated a Buy rating and set a $1,500 price target, a level that implies meaningful upside from recent trading, according to the summarized report.
The commentary places Lilly alongside other large-cap healthcare names as beneficiaries of strong pipelines and structural demand, with the obesity and diabetes franchises central to the investment case. Details of the model assumptions remain proprietary to Citi.
Midweek check on expectations
Consensus data show that most covering analysts also rate Lilly positively, with Buy or equivalent ratings dominating, while only a handful recommend holding the stock, according to aggregated broker surveys on major data platforms.
Market data providers currently cite a market capitalization of about $1.06 trillion for Eli Lilly, underlining its position among the largest healthcare companies globally and within the Standard & Poor's 500 index. Public.com lists that valuation figure as of mid-June 2026.
How Eli Lilly makes its money
Eli Lilly generates the bulk of its revenue from prescription medicines in areas such as diabetes, obesity, oncology and immunology. Key products include the diabetes and obesity drug Mounjaro/Zepbound and other treatments that target chronic diseases with large patient populations.
Where the stock trades today
The shares of Eli Lilly & Co. (US5324571083) trade on the New York Stock Exchange under the ticker LLY; recent quotes put the stock around $1,121.50 on 06/16/2026, based on available market data in USD.
Key facts on Eli Lilly stock
- Company: Eli Lilly & Co.
- ISIN: US5324571083
- WKN: 858560
- Ticker: LLY
- Venue: NYSE
- Price (as of 06/16/2026, 21:59 CET): 1,121.50 USD
- Market cap: 1.06 trillion USD (as of 06/16/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
